Synagis

EUEMA:by INNUSDailyMed:Palivizumab J06BD01(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 188039-54-5Y DB00110Y none DQ448MW7KS D02737 ChEMBL1201586N Palivizumab, sold under the brand nameSynagis, is amonoclonal antibodyproduced byrecombinant DNAtechnology used to prevent severe disease caused byrespiratory syncytial virus(RSV) infections.It is recommended for infants at high-risk for RSV due to conditions such asprematurityor other medical problems includingheartorlungdiseases. The most common side effects includefeverandrash. Palivizumab is ahumanizedmonoclonal antibody (IgG) directed against anepitopein the A antigenic site of the F protein of RSV. In twophase III clinical trialsin the pediatric population, palivizumab reduced the risk of hospitalization due to RSV infection by 55% and 45%.Palivizumab is dosed once a month viaintramuscular (IM) injectionto be administered throughout the RSV season,which tends to start in late autumn or early winter in temperate climates and follows more complicated seasonal patterns in tropical regions. Palivizumab targets the fusion protein of RSV,inhibiting its entry into the cell and thereby preventing infection. Palivizumab was approved for medical use in 1998.